Thymidine labeling index in breast cancer prognosis

Breast Journal

Volumn 4, Issue 1, 1998, Pages 41-48

  Iǧci, Abdullah ^a,b   Berber, Eren ^a   Müslümanoǧlu, Mahmut ^a   Bilir, Ayhan ^a   Özmen, Vahit ^a   Güloǧlu, Recep ^a   Bozfakioǧlu, Yavuz ^a   Daǧoǧlu, Temel ^a   Keçer, Mustafa ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Breast cancer; Prognostic factors; Thymidine labeling index (TLI)

Indexed keywords

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; PROGNOSIS;

EID: 0031937944     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.1998.410041.x     Document Type: Article

References (19)

1. Meyer JS, Koehm SL, Hughes JM, Higa E, Witliff JL, Lagos JA, Manes JL. Bromodeoxyuridine labeling for S-phase measurement in breast carcinoma. Cancer 1993;71(11):3531-40.
2. Meyer JS, Province M. S-phase fraction and nuclear size in long term prognosis of patients with breast cancer. Cancer 1994;74(8):2287-99.
3. Daidone MG, Silvestrini R, Valentinis B, et al. Proliferative activity of primary breast cancer and of synchronous lymph node metastases evaluated by (3H)thymidine labelling index. Cell Tissue Kinet 1990;23:401-8.
4. Meyer JS, McDivit R. Reliability and stability of the thymidine labeling index of breast carcinoma. Lab Invest 1986;54:160-64.
5. Meyer JS, Friedman E, McCrate M, Bauer WC. Prediction of early course of breast carcinoma by thymidine labelling. Cancer 1983;51:1879-86.
6. Tubiana M, Pejovic MH, Chavaudra N, Contesso G, Malaise EP. The long term prognostic significance of the thymidine labelling index in breast cancer. Int J Cancer 1984;33: 441-45.
7. Meyer JS, Province M. Proliferative index of breast carcinoma by thymidine labeling: Prognostic power independent of stage, estrogen and progestreone receptors. Breast Cancer Res Treat 1988;12:191-204.
8. Meyer JS, Prey MV, Babcock DS, McDivit RW. Breast carcinoma cell kinetics, morphology, stage and host characteristics. A thymidine labeling study. Lab I 1986;54:41-51.
9. Gentilli C, Stanfilippo O, Silvestrini R. Cell proliferation and its relation to clinical features and relapse in breast cancer. Cancer 1981;48:974-79.
10. Silvestrini R, Daidone MG, DiFronzo G. Relationship between proliferative activity and estrogen receptors in breast cancer. Cancer 1979;44:665-70.
11. Tubiana M, Koscianly S. Natural history of human breast cancer: Recent data and clinical implications. Breast Cancer Res Treat (Netherlands) 1991;18:125-40.
12. Silvestrini R, Daine MG, Mastore M. Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy. J Clin Oncol (United States) 1993;11: 1150-55.
13. Meyer JS, Province M. Nuclear size (NS), thymidine labeling index, estrogen and progestreone receptors (ER,PgR), tumor size (TS) and lymph node status (N) in long term prognosis of breast carcinoma. Proceedings Am Assoc Cancer Res 1989;154.
14. Silvestrini R, Daidone MG, Gasparini G. Cell kinetics as a prognostic marker in node negative breast cancer. Cancer 1985;56:1982-87.
15. Silvestrini R. Cell kinetics. Prognostic and therapeutic implications in human tumors. Cell Proliferation 1993;26: 361-97.
16. Costa A, Silvestrini R, Grignolio E, et al. Cell kinetics as a prognostic tool in patients with metastatic malignant melanoma of skin. Cancer 1987;60:2797-800.
17. Meyer JS, Hixon B. Advanced stage and early relapse breast carcinomas associated with high Thymidine labeling indices. Cancer Res 1979;39:4042-47.
18. Costa A, Daidone MG, Silvestrini R. Cell proliferation of human tumors and its clinical implications. Cell Proliferation 1993;26:461-500.
19. Meyer JS, Lee JY. Relationship of S-phase fractions of breast carcinoma in response to duration of remission, estrogen receptor content, therapeutic responsiveness and duration of survival. Cancer Res 1980;40:1890-96.